HomeCompareTRXPF vs MRK

TRXPF vs MRK: Dividend Comparison 2026

TRXPF yields 3.27% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRXPF wins by $634.88M in total portfolio value
10 years
TRXPF
TRXPF
● Live price
3.27%
Share price
$24.57
Annual div
$0.80
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$634.94M
Annual income
$599,684,359.43
Full TRXPF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — TRXPF vs MRK

📍 TRXPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRXPFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRXPF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRXPF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRXPF
Annual income on $10K today (after 15% tax)
$277.78/yr
After 10yr DRIP, annual income (after tax)
$509,731,705.52/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, TRXPF beats the other by $509,723,377.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRXPF + MRK for your $10,000?

TRXPF: 50%MRK: 50%
100% MRK50/50100% TRXPF
Portfolio after 10yr
$317.50M
Annual income
$299,847,078.78/yr
Blended yield
94.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TRXPF
No analyst data
Altman Z
5.8
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRXPF buys
0
MRK buys
0
No recent congressional trades found for TRXPF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRXPFMRK
Forward yield3.27%2.76%
Annual dividend / share$0.80$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$634.94M$56.8K
Annual income after 10y$599,684,359.43$9,798.13
Total dividends collected$632.35M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRXPF vs MRK ($10,000, DRIP)

YearTRXPF PortfolioTRXPF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,354$653.59$11,206$366.19+$148.00TRXPF
2$13,535$1,387.04$12,650$502.35+$885.00TRXPF
3$17,574$3,090.80$14,407$694.19+$3.2KTRXPF
4$26,305$7,500.82$16,585$967.82+$9.7KTRXPF
5$49,132$20,985.78$19,342$1,363.89+$29.8KTRXPF
6$125,837$73,265.77$22,913$1,947.19+$102.9KTRXPF
7$485,391$350,745.93$27,662$2,823.89+$457.7KTRXPF
8$3,048,220$2,528,851.81$34,159$4,173.35+$3.01MTRXPF
9$32,945,707$29,684,110.82$43,337$6,308.80+$32.90MTRXPF
10$634,936,266$599,684,359.43$56,776$9,798.13+$634.88MTRXPF

TRXPF vs MRK: Complete Analysis 2026

TRXPFStock

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CORECTIM, a topical janus kinase (JAK) inhibitor. It markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.

Full TRXPF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TRXPF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRXPF vs SCHDTRXPF vs JEPITRXPF vs OTRXPF vs KOTRXPF vs MAINTRXPF vs JNJTRXPF vs ABBVTRXPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.